Patents by Inventor Xiao-Yan Zhao

Xiao-Yan Zhao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11170018
    Abstract: A computer-implemented method, system and computer program product for identifying an appropriate contact across collaborative applications. Contact information is collected from monitored messages, communication lists and contact lists in each collaborative application. Contact records are generated based on the collected contact information, where such records are inserted into a contact list. After receiving a query from a user containing a keyword(s) that include a nickname (or portion thereof) of a second user whom the user desires to interact via the current collaborative application, a search is performed in the contact list for any record containing a nickname that is similar to the provided keyword(s). Record(s) in the contact list containing a nickname that exceeds a threshold degree of similarity as the keyword(s) are identified.
    Type: Grant
    Filed: August 26, 2019
    Date of Patent: November 9, 2021
    Assignee: International Business Machines Corporation
    Inventors: Lei Gao, Xiao Ming Ma, Wu Yan, Xu Qin Zhao, Shuang Li
  • Patent number: 11077187
    Abstract: Provided are optimized humanized antibodies that selectively bind to and inhibit activated protein C without binding to or inhibiting unactivated protein C. In particular, the antibodies bind to particular epitopes outside the catalytic triad of the active site of human activated protein C. Methods of treatment employing these antibodies are described herein.
    Type: Grant
    Filed: November 15, 2016
    Date of Patent: August 3, 2021
    Assignee: OKLAHOMA MEDICAL RESEARCH FOUNDATION
    Inventors: Xiao-Yan Zhao, Andreas Wilmen, Christoph Freiberg, Lars Linden, Ji-Yun Kim, Subramanian Yegneswaran, Karin Regnstrom, Ursula Egner, Xinquan Wang
  • Publication number: 20180326053
    Abstract: Provided are optimized humanized antibodies that selectively bind to and inhibit activated protein C without binding to or inhibiting unactivated protein C. In particular, the antibodies bind to particular epitopes outside the catalytic triad of the active site of human activated protein C. Methods of treatment employing these antibodies are described herein.
    Type: Application
    Filed: November 15, 2016
    Publication date: November 15, 2018
    Inventors: Xiao-Yan ZHAO, Andreas WILMEN, Christoph FREIBERG, Lars LINDEN, Ji-Yun KIM, Subramanian YEGNESWARAN, Karin REGNSTROM, Ursula EGNER, Xinquan WANG
  • Patent number: 10035840
    Abstract: Targeted coagulation factors comprising a coagulation factor linked with at least one domain that specifically binds to a membrane protein on a blood cell is provided. The disclosed targeted coagulation factors increase the efficiency of coagulation factors and prolong their duration of action and thus, are an improvement for the treatment of hematological diseases such as hemophilia A.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: July 31, 2018
    Assignee: Bayer HealthCare LLC
    Inventors: Richard Feldman, Ji-Yun Kim, Haiyan Jiang, Kirk McLean, Junliang Pan, Glenn Pierce, James Wu, Xiao-Yan Zhao
  • Patent number: 9657111
    Abstract: Provided are humanized antibodies that selectively bind to and inhibit activated protein C without binding to or inhibiting unactivated protein C. Methods of treatment employing these antibodies are described herein.
    Type: Grant
    Filed: November 27, 2013
    Date of Patent: May 23, 2017
    Assignee: BAYER HEALTHCARE LLC
    Inventors: Xiao-Yan Zhao, Zhuozhi Wang, Ji-Yun Kim, Ying Zhu, Jan Tebbe
  • Publication number: 20170051042
    Abstract: Targeted coagulation factors comprising a coagulation factor linked with at least one domain that specifically binds to a membrane protein on a blood cell is provided. The disclosed targeted coagulation factors increase the efficiency of coagulation factors and prolong their duration of action and thus, are an improvement for the treatment of hematological diseases such as hemophilia A.
    Type: Application
    Filed: July 28, 2016
    Publication date: February 23, 2017
    Inventors: Richard FELDMAN, Ji-Yun KIM, Haiyan JIANG, Kirk MCLEAN, Junliang PAN, Glenn PIERCE, James WU, Xiao-Yan ZHAO
  • Patent number: 9422362
    Abstract: Targeted coagulation factors comprising a coagulation factor linked with at least one domain that specifically binds to a membrane protein on a blood cell is provided. The disclosed targeted coagulation factors increase the efficiency of coagulation factors and prolong their duration of action and thus, are an improvement for the treatment of hematological diseases such as hemophilia A.
    Type: Grant
    Filed: April 15, 2014
    Date of Patent: August 23, 2016
    Assignee: BAYER HEALTHCARE LLC
    Inventors: Richard Feldman, Ji-Yun Kim, Haiyan Jiang, Kirk Mclean, Junliang Pan, Glenn Pierce, James Wu, Xiao-Yan Zhao
  • Publication number: 20150322164
    Abstract: Provided are humanized antibodies that selectively bind to and inhibit activated protein C without binding to or inhibiting unactivated protein C. Methods of treatment employing these antibodies are described herein.
    Type: Application
    Filed: November 27, 2013
    Publication date: November 12, 2015
    Applicant: BAYER HEALTHCARE LLC
    Inventors: Xiao-Yan ZHAO, Zhuozhi WANG, Ji-Yun KIM, Ying ZHU, Jan TEBBE
  • Publication number: 20150307625
    Abstract: Provided herein are antibodies, antigen-binding antibody fragments (Fabs), and other protein scaffolds, directed against human activated Protein C (aPC) with minimal binding to its zymogen Protein C (PC). Moreover, these aPC binding proteins could potentially block the anti-coagulant activity of aPC to induce coagulation. Therapeutic uses of these binders are described herein as are methods of panning and screening specific antibodies.
    Type: Application
    Filed: November 27, 2013
    Publication date: October 29, 2015
    Applicant: BAYER HEALTHCARE LLC
    Inventors: Xiao-Yan ZHAO, Zhuozhi WANG, Jian-Ming GU, Ji-Yun KIM, Maxine BAUZON, John E. MURPHY, Kirk MCLEAN, Fang JIN, Tobias MARQUARDT, Xinquan WANG, Andreas WILMEN
  • Publication number: 20140221618
    Abstract: Targeted coagulation factors comprising a coagulation factor linked with at least one domain that specifically binds to a membrane protein on a blood cell is provided. The disclosed targeted coagulation factors increase the efficiency of coagulation factors and prolong their duration of action and thus, are an improvement for the treatment of hematological diseases such as hemophilia A.
    Type: Application
    Filed: April 15, 2014
    Publication date: August 7, 2014
    Inventors: Richard Feldman, Ji-Yun Kim, Haiyan Jiang, Kirk Mclean, Junliang Pan, Glenn Pierce, James Wu, Xiao-Yan Zhao
  • Publication number: 20120142593
    Abstract: A Factor VIII fusion protein or a Factor VIII fusion heterodimer comprising Factor VIII in which an amino acid sequence of a modulator is present in the B-domain, or an amino acid sequence of a modulator replaces some or all of the amino acid sequence of the B-domain is disclosed. Nucleic acids encoding the inventive fusion proteins and fusion heterodimers are also disclosed, as are methods for producing the fusion proteins and fusion heterodimers, pharmaceutical compositions, and methods of treating deficiencies in coagulation with the inventive fusion molecules.
    Type: Application
    Filed: March 24, 2010
    Publication date: June 7, 2012
    Applicant: BAYER HEALTHCARE LLC
    Inventors: Xiao-Yan Zhao, Peter John Kretschmer, Thomas Eugene Thompson, Douglas W. Schneider, John Edward Murphy
  • Publication number: 20110077202
    Abstract: Targeted coagulation factors comprising a coagulation factor linked with at least one domain that specifically binds to a membrane protein on a blood cell is provided. The disclosed targeted coagulation factors increase the efficiency of coagulation factors and prolong their duration of action and thus, are an improvement for the treatment of hematological diseases such as hemophilia A.
    Type: Application
    Filed: May 15, 2009
    Publication date: March 31, 2011
    Applicant: BAYER HEALTHCARE LLC
    Inventors: Richard Feldman, Ji-Yun Kim, Haiyan Jiang, Kirk Mclean, Junliang Pan, Glenn Pierce, James Wu, Xiao-Yan Zhao
  • Publication number: 20060292074
    Abstract: The present invention relates to antibodies, and antigen-binding antibody fragments, directed against a Tomoregulin (TR) polypeptide. The invention further relates to methods for utilizing the antibodies, and antibody fragments, for diagnostic and therapeutic applications.
    Type: Application
    Filed: June 23, 2006
    Publication date: December 28, 2006
    Applicant: Schering Aktiengesellschaft
    Inventors: Tara Heitner, David Light, Bing Liu, Noboru Satozawa, Xiao-Yan Zhao